Pacira BioSciences, Inc. (PCRX)
Largest Insider Buys in Sector
PCRX Stock Price History Chart
PCRX Stock Performance
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that …
Insider Activity of Pacira BioSciences, Inc.
Over the last 12 months, insiders at Pacira BioSciences, Inc. have bought $215,684 and sold $4.28M worth of Pacira BioSciences, Inc. stock.
On average, over the past 5 years, insiders at Pacira BioSciences, Inc. have bought $153,467 and sold $18.22M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lee Frank D. (Chief Executive Officer) — $99,994. BIGAL MARCELO (director) — $60,868. YANG MICHAEL J. (director) — $51,600.
The last purchase of 1,512 shares for transaction amount of $20,034 was made by BIGAL MARCELO (director) on 2024‑08‑16.
List of Insider Buy and Sell Transactions, Pacira BioSciences, Inc.
| 2024-09-13 | Sale | Chief Operating Officer | 500 0.0011% | $12.86 | $6,430 | +21.59% | ||
| 2024-08-16 | director | 1,000 0.0023% | $12.81 | $12,810 | +9.13% | |||
| 2024-08-16 | director | 1,512 0.0036% | $13.25 | $20,034 | +5.51% | |||
| 2024-08-14 | director | 2,000 0.0046% | $12.90 | $25,800 | 0.00% | |||
| 2024-08-12 | Chief Executive Officer | 8,264 0.0178% | $12.10 | $99,994 | +23.35% | |||
| 2024-08-12 | director | 1,400 0.0029% | $11.58 | $16,212 | +23.35% | |||
| 2024-08-12 | director | 3,400 0.0073% | $12.01 | $40,834 | +23.35% | |||
| 2024-08-02 | Sale | Chief Medical Officer | 945 0.0019% | $20.05 | $18,947 | -28.32% | ||
| 2024-07-02 | Sale | Chief Medical Officer | 2,836 0.0062% | $28.25 | $80,117 | 0.00% | ||
| 2024-06-13 | Sale | Chief Operating Officer | 1,000 0.0021% | $28.38 | $28,380 | -43.23% | ||
| 2024-06-13 | Sale | Chief Administrative Officer | 7,452 0.0157% | $28.38 | $211,488 | -43.23% | ||
| 2024-06-13 | Sale | director | 880 0.0019% | $28.38 | $24,974 | -43.23% | ||
| 2024-06-12 | Sale | Senior Vice President, Finance | 3,970 0.0085% | $28.72 | $114,018 | -43.44% | ||
| 2024-06-11 | Sale | Chief Medical Officer | 5,012 0.0106% | $28.57 | $143,193 | -43.84% | ||
| 2024-03-08 | Sale | director | 90,000 0.1889% | $30.60 | $2.75M | -16.37% | ||
| 2024-03-07 | Sale | director | 28,257 0.0613% | $30.81 | $870,598 | -14.21% | ||
| 2024-03-06 | Sale | director | 1,066 0.0023% | $29.67 | $31,628 | -12.52% | ||
| 2023-08-02 | Sale | Chief Medical Officer | 509 0.0011% | $34.88 | $17,751 | -19.01% | ||
| 2023-07-05 | Sale | Senior Vice President, Finance | 643 0.0014% | $38.91 | $25,019 | -22.50% | ||
| 2023-06-14 | Sale | Chief Administrative Officer | 6,467 0.0135% | $37.03 | $239,473 | -21.58% |
Insider Historical Profitability
| Lee Frank D. | Chief Executive Officer | 107784 0.2337% | $17.57 | 1 | 0 | |
| PACE GARY W | director | 22127 0.048% | $17.57 | 5 | 6 | +11.64% |
| Brege Laura | director | 17552 0.0381% | $17.57 | 1 | 6 | |
| Froimson Mark | director | 14473 0.0314% | $17.57 | 2 | 2 | <0.0001% |
| HASTINGS PAUL J | director | 12724 0.0276% | $17.57 | 1 | 18 | +79.52% |
Institutional Investor Ownership
| BlackRock | $230.99M | 16.98 | 7.91M | -2.58% | -$6.11M | 0.01 | |
| The Vanguard Group | $149.41M | 10.99 | 5.11M | +0.29% | +$437,131.20 | <0.01 | |
| Frontier Capital Management Co | $55.94M | 4.11 | 1.91M | -8.16% | -$4.97M | 0.52 | |
| State Street | $55.62M | 4.09 | 1.9M | -1.68% | -$950,994.13 | <0.01 | |
| Renaissance Technologies | $55M | 4.04 | 1.88M | +9.64% | +$4.84M | 0.09 |